TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03316430

Intervention type: OTHER
Intervention: Podocyturia quantification
Description: Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
Study: NCT01524744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus ointment
Description: Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adcortyl
Description: triamcinolone acetonide 0.1% in orabase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adcortyl
Description: triamcinolone acetonide 0.1% in orabase
Study: NCT03770286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% Fluoride Varnish
Description: Topical varnish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5% Fluoride Varnish
Description: Topical varnish
Study: NCT03068637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carevive CPS
Description: This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
Study: NCT00855153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR (Virtual reality)
Description: VR stimulation of combat scenarios utilized as the exposure therapy tool.
Study: NCT03770286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5% Fluoride Varnish
Description: Topical varnish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 38% Silver diamine fluoride
Description: Topical varnish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 38% Silver diamine fluoride
Description: Topical varnish
Study: NCT04423276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Study: NCT00855153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
Study: NCT03101618

Intervention type: OTHER
Intervention: Animal allergy
Description: Allergic symptom occurs during exposure to laboratory or pet animal

Intervention type: OTHER
Intervention: Animal allergy
Description: Allergic symptom occurs during exposure to laboratory or pet animal

Intervention type: OTHER
Intervention: Animal allergy
Description: Allergic symptom occurs during exposure to laboratory or pet animal

Intervention type: OTHER
Intervention: Non-animal allergy
Description: Allergic symptom does not occur during exposure to laboratory or pet animal

Intervention type: OTHER
Intervention: Non-animal allergy
Description: Allergic symptom does not occur during exposure to laboratory or pet animal

Intervention type: OTHER
Intervention: Non-animal allergy
Description: Allergic symptom does not occur during exposure to laboratory or pet animal
Study: NCT03770286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super Floss
Description: Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
Study: NCT04308746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Individualistic Prime (statement writing)
Description: Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Collectivistic Prime (statement writing)
Description: Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
Study: NCT01899872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise session
Description: Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session
Description: Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
Study: NCT03582618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118
Description: CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
Study: NCT04574284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study: NCT02177851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single oral iron dose of 120 mg per day for 3 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
Study: NCT01671241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene wrap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene wrap
Study: NCT02615535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback-assisted meditation
Description: meditation with auditory feedback regarding EEG status
Study: NCT03855995

Intervention type: PROCEDURE
Intervention: Whole blood sample
Description: Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.

Intervention type: PROCEDURE
Intervention: Whole blood sample
Description: Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.

Intervention type: PROCEDURE
Intervention: Whole blood sample
Description: Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.
Study: NCT03379870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting
Description: Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
Study: NCT04395079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT03868111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Study: NCT01629537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block injection with ropivicane
Description: For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placebo Procedure
Description: In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
Study: NCT00862537

Intervention type: DEVICE
Intervention: Resonator Device
Description: active pico-tesla magnetic fields treatment for Parkinson's disease individuals
Study: NCT04290234

Intervention type: OTHER
Intervention: fMRI assessment of cognitive and reactive fear
Description: An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
Study: NCT01062334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal Microdialysis, CT-scan, leakage scoring
Description: Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
Study: NCT01531504

Intervention type: DEVICE
Group type: OTHER
Intervention: ViKY UP
Description: laparoscopic-assisted hysterectomy procedure
Study: NCT03367936

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one Session
Description: Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one Session
Description: Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Participants will receive an orientation on how to self-monitor using the smartphone and other devises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will receive an orientation on how to self-monitor using the smartphone and other devises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
Study: NCT03863041

Intervention type: OTHER
Group type: OTHER
Intervention: Additional sequence performed during MRI scan
Description: An additional sequence will be performed during the MRI scan.
Study: NCT01348204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quercetin
Description: health food supplement
Study: NCT01017094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silversulfadiazine
Description: apply once a day
Study: NCT04615533

Intervention type: OTHER
Intervention: Frail older adults, assessment
Description: Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
Study: NCT00747331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesilate
Description: Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug
Study: NCT01553383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal peep valve Provent
Description: application of nasal peep valve vs dental device and cpap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal peep valve Provent
Description: application of nasal peep valve vs dental device and cpap
Study: NCT03289858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Subcutaneous injection at conclusion of surgical fixation of hip fracture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Saline Injection
Study: NCT00839722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: fertility after embolization
Study: NCT02201849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01501370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
Study: NCT03643575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicks Cough Syrup for Chesty Coughs
Description: Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Robitussin Extra Strength Chest Congestion
Description: Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Organ-I- NR tablet
Description: Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
Study: NCT02824575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: 50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebastinib
Description: 50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
Study: NCT01000402

Intervention type: DRUG
Group type: OTHER
Intervention: Psychopharmacotherapy
Description: Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
Study: NCT02183896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT05393011

Intervention type: DRUG
Intervention: human chorionic gonadotropin
Description: 10000 IU when at least three follicles become more than 16 mm

Intervention type: DRUG
Intervention: human chorionic gonadotropin
Description: 10000 IU when at least three follicles become more than 16 mm
Study: NCT02508857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
Study: NCT04391361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine, atropine, edaravone and dexmedetomidine
Description: The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edaravone
Description: The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
Study: NCT03477123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking therapy with Exo-H2 exoskeleton
Study: NCT02462252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: horse anti-thymocyte globulin (hATG)
Description: From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
Study: NCT04354142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSpy
Description: iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
Study: NCT03611491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Princess FILLER Lidocaine
Description: Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
Study: NCT01524731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg
Study: NCT01034150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relief band (Somatosensory stimulation)
Description: Electrical median nerve stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stimulation
Description: Placebo stimulation
Study: NCT03870100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous
Study: NCT03379870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic Speech Processor: Full-electric stimulation fitting
Description: Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
Study: NCT00297791

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: randomized to open or laparoscopic technique
Study: NCT01598948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
Study: NCT02615535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-EEG feedback-assisted meditation
Description: meditation without auditory feedback regarding EEG status
Study: NCT03662399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles
Study: NCT00551824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
Study: NCT03662399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard shoe
Description: Standard shoe
Study: NCT02404337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine